1. |
- Borgmästars, Emmy, 1990-
(author)
-
In search of early biomarkers in pancreatic ductal adenocarcinoma using multi-omics and bioinformatics
- 2022
-
Doctoral thesis (other academic/artistic)abstract
- Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year survival of 10 %. Surgery is the only curative treatment. Unfortunately, few patients are eligible for surgery due to late detection. Thus, we need ways to detect the disease at an earlier stage and for that good screening biomarkers could be used. Previous studies have analyzed circulating analytes in prospective studies to identify early PDAC signals. One such class is microRNAs (miRNAs). MicroRNAs are non-coding RNAs of around 22 nucleotides that act as post- transcriptional regulators by interaction with messenger RNAs (mRNAs). The function of a miRNA can be elucidated by target prediction, to identify its potential targets, followed by enrichment analysis of the predicted targets. Challenges with this approach includes a lot of false positives being generated and that miRNAs can perform their role in a tissue- or disease-specific manner. Other classes of analytes that have previously been studied in prospective PDAC cohorts are metabolites and proteins. Aims: This thesis has three aims. First, to build a miRNA functional analysis pipeline with correlation support between miRNA and its predicted target genes. Second, to identify potential circulating biomarkers for early detection of PDAC using multi-omics. Third, to identify potential prognostic metabolites in a prospective PDAC cohort.Methods: We used publicly available data from the cancer genome atlas-pancreatic adenocarcinoma (TCGA-PAAD) and pre-diagnostic plasma samples from the Northern Sweden Health and Disease Study. We built a pipeline in R including miRNA, mRNA, and protein expression data from TCGA-PAAD for in silico miRNA functional analysis. Pre- diagnostic plasma samples from future PDAC patients as well as matched healthy controls were analyzed using multi- omics. Tissue polypeptide specific antigen (TPS) was analyzed by enzyme linked immunosorbent assay in 267 future PDAC samples and 320 healthy controls. Metabolomics and clinical biomarkers (carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), and CA 15-3) were profiled in 100 future PDAC samples and 100 healthy controls using liquid chromatography-mass spectrometry (MS), gas chromatography-MS, and multi-plex technology. Of these, a subset of 39 future PDAC patients and 39 healthy controls were profiled for 2083 microRNAs using targeted sequencing and 644 proteins using proximity extension assays. Circulating levels of multi-omics analytes were analyzed using conditional or unconditional logistic regression. Least absolute shrinkage and selection operator (LASSO) in combination with 500 bootstrap iterations identified the most informative variables. The prognostic value of metabolites was assessed using cox regression. Multi-omics factor analysis (MOFA) and data integration analysis for biomarker discovery using latent components (DIABLO) were used for multi-omics integration analyses.Results: An automated pipeline was built consisting of 1) miRNA target prediction, 2) correlation analyses between miRNA and its targets on mRNA and protein expression levels, and 3) functional enrichment of correlated targets to identify enriched Kyoto encyclopedia of genes and genomes (KEGG) pathways and gene ontology (GO) terms for a specific miRNA. The pipeline was run for all microRNAs (~700) detected in the TCGA-PAAD cohort. These results can be downloaded from a shiny app (https://emmbor.shinyapps.io/mirfa/). TPS was not altered in pre-diagnostic PDAC patients up to 24 years prior to diagnosis, but increased at diagnosis (OR = 1.03, 95 % CI: 1.01-1.05). Internal area under curves of 0.74, 0.80, and 0.88 were achieved for five metabolites, two proteins, and two miRNAs that were selected by LASSO and bootstrap iterations, in combination with CA 19-9. Neither MOFA nor DIABLO separated well between future PDAC cases and healthy controls. Conclusions: Our bioinformatics pipeline for in silico functional analysis of microRNAs successfully identifies enriched KEGG pathways and GO terms for miRNA isoforms. The investigated plasma samples are heterogeneous, but among the analyzed variables, we identified five metabolites, two proteins, and two microRNAs with highest potential for early PDAC detection. CA 19-9 levels increased closer to diagnosis. We identified five fatty acids that could be studied in a diagnostic PDAC cohort as prognostic biomarkers.
|
|
2. |
- Badam, Tejaswi Venkata Satya, 1989-
(author)
-
Omic Network Modules in Complex diseases
- 2021
-
Doctoral thesis (other academic/artistic)abstract
- Biological systems encompass various molecular entities such as genes, proteins, and other biological molecules, including interactions among those components. Understanding a given phenotype, the functioning of a cell or tissue, aetiology of disease, or cellular organization, requires accurate measurements of the abundance profiles of these molecular entities in the form of biomedical data. The analysis of the interplay between these different entities at various levels represented in the form of biological network provides a mechanistic understanding of the observed phenotype. In order to study this interplay, there is a requirement of a conceptual and intuitive framework which can model multiple omics such as genome, transcriptome, or a proteome. This can be addressed by application of network-based strategies.Translational bioinformatics deals with the development of analytic and interpretive methods to optimize the transformation of different omics and clinical data to understanding of complex diseases and improving human health. Complex diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and non-small cell lung cancer (NSCLC) etc., are hypothesized to be a result of a disturbance in the omic networks rendering the healthy cells to be in a state of malfunction. Even though there are numerous methods to layout the relation of the interactions among omics in complex diseases, the output network modules were not clearly interpreted.In this PhD thesis, we showed how different omic data such as transcriptome and methylome can be mapped to the network of interactions to extract highly interconnected gene sets relevant to the disease, so called disease modules. First, we selected common module identification methods and assembled them into a unified framework of the methods implemented in an Rpackage MODifieR (Paper I). Secondly, we showed that the concept of the network modules can be applied on the whole genome sequencing data for developing a tested model for predicting myelosuppressive toxicity (Paper II).Furthermore, we demonstrated that network modules extracted using the methylome data helped identifying several genes that were associated with pregnancy-induced pathways and were enriched for disease-associated methylation changes that were also shared by three auto-immune and inflammatory diseases, namely MS, RA, and SLE (Paper III). Remarkably, those methylation changes correlated with the expected outcome from clinical experience in those diseases. Last, we benchmarked the omic network modules on 19 different complex diseases using both transcriptomic and methylomic data. This led to the identification of a multi-omic MS module that was highly enriched disease-associated genes identified by genome-wide association studies, but also genes associated with the most common environmental risk factors of MS (Paper IV).The application of the network modules concept on different omics is the centrepiece of the research presented in this PhD thesis. The thesis represents the application of omic network modules in complex diseases and how these modules should be integrated and interpreted. In particular, it aimed to show the importance of networks owing to the incomplete knowledge of the genes dysregulated in complex diseases and the contribution of this thesis that provides tools and benchmarks for the methods as well as insights into how a network module can be extracted and interpreted from the omic data in complex diseases.
|
|